{
    "ticker": "KRON",
    "name": "Kronos Bio, Inc.",
    "description": "Kronos Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with cancer and other serious diseases. Founded in 2018, the company is driven by a passion for advancing the science of precision medicine. Kronos Bio leverages deep expertise in cell biology, genomics, and drug discovery to create targeted therapies that aim to address the underlying causes of cancer. The company\u2019s lead product candidate, KB-0742, is a potent and selective inhibitor of the transcription factor MYC, which is implicated in numerous types of cancer. With a robust clinical development pipeline, Kronos Bio is committed to delivering new treatment options that can improve patient outcomes in oncology. The company is also exploring additional therapeutic areas and novel mechanisms of action to expand its impact in the biopharmaceutical landscape. Kronos Bio is headquartered in San Mateo, California, and operates with a strong focus on collaboration and partnership with leading academic institutions and research organizations to accelerate drug discovery and development. The company's mission is to transform the lives of patients by providing effective, life-changing therapies.",
    "industry": [
        "Biopharmaceuticals",
        "Healthcare"
    ],
    "headquarters": "San Mateo, California, USA",
    "founded": "2018",
    "website": "https://www.kronosbio.com",
    "ceo": "Erik E. B. D. H. D. P. F. D. P. H. D. G. R. H. D. G. R. H. D. P. H. D. R. H. D.",
    "social_media": {
        "twitter": "https://twitter.com/kronosbio",
        "linkedin": "https://www.linkedin.com/company/kronos-bio/"
    },
    "investor_relations": "https://investors.kronosbio.com",
    "key_executives": [
        {
            "name": "Norbert Bischofberger",
            "position": "CEO & President"
        },
        {
            "name": "Eric R. R. R. R. R.",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Clinical Programs",
            "products": [
                "KB-0742"
            ]
        }
    ],
    "seo": {
        "meta_title": "Kronos Bio, Inc. | Innovative Cancer Therapies",
        "meta_description": "Kronos Bio, Inc. is dedicated to developing innovative therapies for cancer and serious diseases through precision medicine. Explore our pipeline and mission.",
        "keywords": [
            "Kronos Bio",
            "Biopharmaceuticals",
            "Cancer Treatment",
            "Precision Medicine",
            "KB-0742"
        ]
    },
    "faq": [
        {
            "question": "What does Kronos Bio focus on?",
            "answer": "Kronos Bio focuses on developing innovative therapies for cancer and serious diseases."
        },
        {
            "question": "Where is Kronos Bio headquartered?",
            "answer": "Kronos Bio is headquartered in San Mateo, California, USA."
        },
        {
            "question": "What is Kronos Bio's lead product candidate?",
            "answer": "Kronos Bio's lead product candidate is KB-0742, a MYC inhibitor."
        },
        {
            "question": "When was Kronos Bio founded?",
            "answer": "Kronos Bio was founded in 2018."
        }
    ],
    "competitors": [
        "MRNA",
        "KITE",
        "CRSP",
        "EDIT"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "NVS",
        "ABBV"
    ]
}